Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 8Sinonasal undifferentiated carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1

Interventions

Biopsy 9Specimen Handling 8Magnetic Resonance Spectroscopy 6duvelisib 5Cyclophosphamide 5ruxolitinib 4Vincristine 410-propargyl-10-deazaaminopterin 4pembrolizumab 3X-Rays 3Prednisone 3Etoposide 3Doxorubicin 3tazemetostat 2sodium-iodide symporter 2cemiplimab 2belinostat 2Photons 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immunoglobulin G 2Disulfides 2Cytarabine 2Bortezomib 2Azacitidine 2venetoclax 1talimogene laherparepvec 1romidepsin 1prednylidene 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × enasidenib × 90 days × Clear all
NCT06756308 2026-04-07

A Study of Enasidenib in People With T-Cell Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
25 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡